Search results
Results from the WOW.Com Content Network
Ciprofloxacin is 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid. Its empirical formula is C 17 H 18 FN 3 O 3 and its molecular weight is 331.4 g/mol. It is a faintly yellowish to light yellow crystalline substance. [68] Ciprofloxacin hydrochloride is the monohydrochloride monohydrate salt of ciprofloxacin ...
ATC code J01 Antibacterials for systemic use is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
I (User:MattKingston) am in the process of creating a list of drugs and their various names. The list will be alphabetical and will use the following format (subject to change if better suggestions are put forward). All items in the list will follow the general format: Name of drug (who calls it that) [country]. Redirects to name of drug.
Ciprofloxacin, a fluoroquinolone antibiotic, has shown in vitro activity against many Gram-positive and Gram-negative bacteria including Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Pseudomonas aeruginosa.
Hexion Inc. or Hexion (previously Momentive Specialty Chemicals) [2] is a chemical company based in Columbus, Ohio.It produces thermoset resins and related technologies and specialty products.
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles ; try the Find link tool for suggestions. ( December 2023 )
Other than this and one other clinical trial into its efficacy as a treatment for pneumocystis pneumonia, [60] data on its use in both the treatment and prevention of pneumocystis pneumonia is significantly lacking. Toxoplasmosis: Yes: Prevention only: Yes: Clinical trials have confirmed its prophylactic and therapeutic utility in cases of ...
Within one review prulifloxacin was stated to have a similar tolerability profile to that of ciprofloxacin. [15] Within another study it was found that prulifloxacin patients experienced a similar number of adverse reactions compared to those in the ciprofloxacin group (15.4% vs 12.7%).